These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 34140296)
1. A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. Ryerson CJ; Corte TJ; Myers JL; Walsh SLF; Guler SA Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34140296 [TBL] [Abstract][Full Text] [Related]
2. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival. Hyldgaard C Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544 [TBL] [Abstract][Full Text] [Related]
3. Unclassifiable interstitial lung disease: from phenotyping to possible treatments. Guler SA; Ryerson CJ Curr Opin Pulm Med; 2018 Sep; 24(5):461-468. PubMed ID: 30004990 [TBL] [Abstract][Full Text] [Related]
14. Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. Ferri C; Manfredi A; Sebastiani M; Colaci M; Giuggioli D; Vacchi C; Della Casa G; Cerri S; Torricelli P; Luppi F Autoimmun Rev; 2016 Jan; 15(1):61-70. PubMed ID: 26384526 [TBL] [Abstract][Full Text] [Related]
15. The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases. Ageely G; Souza C; De Boer K; Zahra S; Gomes M; Voduc N Can Respir J; 2020; 2020():9026171. PubMed ID: 32879642 [TBL] [Abstract][Full Text] [Related]
17. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637 [TBL] [Abstract][Full Text] [Related]
18. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Makino S Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Guler SA; Ellison K; Algamdi M; Collard HR; Ryerson CJ Ann Am Thorac Soc; 2018 Jul; 15(7):854-863. PubMed ID: 29779392 [TBL] [Abstract][Full Text] [Related]
20. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M; Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]